NCT00092170

An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)

A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (planned)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 3 Months – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.

Detailed description

The duration of treatment is 18 months.

Conditions

• Infections
• Pelvic Infections

Interventions

Type	Name	Description
DRUG	MK0826, ertapenem sodium
DRUG	Comparator: Ticarcillin/Clavulanate

Timeline

• Start date: 2002-03-01
• Primary completion: 2004-01-01
• Completion: 2004-01-01
• First posted: 2004-09-24
• Last updated: 2017-02-17